Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study
https://doi.org/10.4081/aiua.2021.4.393
Accepted: August 15, 2021
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Introduction: Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer but there is a lack of quality evidence regarding which is associated with better outcomes and who would benefit the most with one or another of these drugs.
Objective: To evaluate the clinical outcomes of real-world patients submitted to treatment with novel hormonal agents, enzalutamide and abiraterone, for castration resistant metastatic prostate cancer in an academic center.
Patients and methods: We retrospectively reviewed patients treated for castration-resistant prostate cancer with either abiraterone or enzulatamide between January 1, 2016 and December 31, 2019. The primary endpoints were biochemical response, biochemical progression, radiological progression, clinical deterioration (attributed to disease progression) and death.
Results: Enzalutamide had a higher biochemical response rate than abiraterone in patients with mCRPC (77.1% vs 58.1%, p = 0.016). Achieving a biochemical response was associated with a lower risk of biochemical progression (OR: 0.248, p = 0.017) and death (OR: 0.302, p = 0.038).
Conclusions: Enzalutamide conferred higher biochemical response rate than abiraterone in patients with mCRPC. Despite the trend to better performance of other endpoints in the enzalutamide group, it did not achieve statistical significance. Well-designed prospective studies are needed to elucidate the comparative efficacies of these agents.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13:983-92. DOI: https://doi.org/10.1016/S1470-2045(12)70379-0
Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371:424-33. DOI: https://doi.org/10.1056/NEJMoa1405095
Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97. DOI: https://doi.org/10.1056/NEJMoa1207506
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16:152-60. DOI: https://doi.org/10.1016/S1470-2045(14)71205-7
Wang X, Yang H, Hu X, et al. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castrationresistant prostate cancer: A systematic review and meta-analysis. J Oncol Pharm Pract. 2021; 27:614-622. DOI: https://doi.org/10.1177/1078155220929414
Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019; 20:1730-9. DOI: https://doi.org/10.1016/S1470-2045(19)30688-6
Hung SC, Wang SS, Li JR, et al. Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA
Progression with Abiraterone Acetate. Anticancer Res. 2018;38:5429-36. DOI: https://doi.org/10.21873/anticanres.12874
Miyake H, Hara T, Terakawa T, et al. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017; 15:313-9. DOI: https://doi.org/10.1016/j.clgc.2016.06.010
Heo MH, Park SH, Kim HK, et al. Overall survival beyond firstline docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide. J Clin Oncol. 2017; 35(6_suppl):e570-e570. DOI: https://doi.org/10.1200/JCO.2017.35.6_suppl.e570
Norris T, Walter S, Williams A, et al. Comparison of Toxicity and Efficacy Outcomes of Abiraterone and Enzalutamide in 198 Patients with Metastatic Castrate Resistant Prostate Cancer. Clin Oncol. 2017; 29:e87-8. DOI: https://doi.org/10.1016/j.clon.2016.11.020
García AS, Mateos AA, Esquerdo ML, et al. 4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. Eur J Hosp Pharm. 2018;25(Suppl 1):A101-A101. DOI: https://doi.org/10.1136/ejhpharm-2018-eahpconf.219
Khalaf D, Zou K, Struss WJ, et al. Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study. J Clin Oncol. 2018; 36(15_suppl):5051-5051. DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.5051
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
